FDA ReviewedUpdated July 5, 2026

Zepbound Guide

Zepbound is the brand-name formulation of tirzepatide 2.5–15mg specifically FDA-approved for chronic weight management, launched by Eli Lilly in late 2023. It is chemically identical to Mounjaro but approved specifically for obesity treatment, making it eligible for different insurance coverage pathways and savings programs.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

By Eli Marsden · Founding Editor
Editorially reviewed (not clinically reviewed) · How we verify contentLast reviewed

At a Glance

Generic NameTirzepatide
Brand NamesZepbound
FDA StatusFDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity (November 2023)[1]
Approval DateNovember 8, 2023[1]

How Zepbound Works

Zepbound works through tirzepatide's dual GIP/GLP-1 mechanism to reduce appetite through both central brain signals and peripheral metabolic effects. GLP-1 activation creates feelings of fullness and slows digestion; GIP activation may additionally enhance fat metabolism and energy expenditure. This twin-hormone approach produces more weight loss than any single-pathway agent.[2]

Dosing Schedule

Zepbound uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].

Weeks 1–42.5mg/week
Weeks 5–85mg/week
Weeks 9–127.5mg/week
Weeks 13–1610mg/week
Weeks 17–2012.5mg/week
Week 21+15mg/week (maintenance)

Side Effects

Common: nausea (31%), diarrhea (23%), vomiting (13%), constipation (12%), abdominal pain (9%), injection site redness. Nausea is most common during dose escalation and typically resolves within a month of each new dose. Serious (rare): pancreatitis, cholelithiasis (gallstones), suicidal ideation monitoring recommended, thyroid tumor risk noted in animal models.[1][2]

This is not a complete list. Consult your healthcare provider or prescriber for full safety information. The complete adverse reaction profile is published in the current FDA prescribing information[1].

Clinical Trial Results

In the SURMOUNT-1 trial, Zepbound (tirzepatide 15mg) produced an average weight loss of 22.5% (about 52 lbs) over 72 weeks — the highest of any anti-obesity medication ever studied. At 10mg, participants lost 21.4%; at 5mg, they lost 15.0%. 91% of participants lost at least 5% of body weight at the 15mg dose.[2][3]

Source: Published clinical trial data (STEP / SURMOUNT trial series) — see the Sources panel below for full citations.

Where to Get Zepbound

These telehealth providers offer access to tirzepatide or compounded equivalents with online consultations and home delivery.

7.4/ 10
Verified partner

RxSpan MD

Best for: shoppers wanting physician-led, pharmacy-transparent compounded GLP-1 with brand-name options

★★★★☆3.7

Editorial score · methodology

$249/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full RxSpan MD review →
8.4/ 10

GoodRx

Best for: self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies

★★★★☆4.2

Editorial score · methodology

$149/mo
BrandOrforglipronTirzepatide
Get StartedRead full GoodRx review →
7.8/ 10

Knownwell

Best for: Patients wanting branded GLP-1s with obesity-medicine oversight and insurance options

★★★★☆3.9

Editorial score · methodology

$349/mo
BrandTirzepatide
Get StartedRead full Knownwell review →
7.6/ 10

Vaylen

Best for: GLP-1-focused care with oral and injectable options across all 50 states

★★★★☆3.8

Editorial score · methodology

$179/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full Vaylen review →
7.5/ 10

Effecty

Best for: nationwide compounded semaglutide with brand-name fallback

★★★★☆3.8

Editorial score · methodology

$60/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full Effecty review →
7.5/ 10

Klinic

Best for: brand-name Wegovy & Zepbound through insurance (Medicare/Medicaid OK) or self-pay, all 50 states

★★★★☆3.8

Editorial score · methodology

$299/mo
BrandSemaglutideTirzepatide
Get StartedRead full Klinic review →

Cost Comparison

Zepbound cost & pricing →Savings & coupons →Side effects →Dosing & titration →How to get it →

Starting prices for compounded GLP-1 medications from top providers, sorted cheapest first. Compounded tirzepatide from licensed 503A and 503B pharmacies is legal under federal compounding law[4], with additional tolerances historically allowed while the molecule has appeared on the FDA Drug Shortage List[5]. Both compounded and brand-name prescriptions are generally FSA/HSA eligible under IRS Publication 502[6]. Prices may vary based on dose and promo availability.

ProviderStarting Price
The Virtual NP$75/moVisit
Kin Meds$149/moVisit
AskRx$299/moVisit
GoodRx$299/moVisit
Klinic$299/moVisit
Knownwell$349/moVisit
Rex MD$349/moVisit
Aspire Health$374/moVisit
RxSpan MD$1069/moVisit
Vaylen$1086/moVisit
altRX$1249/moVisit
Effecty$1300/moVisit
HeliMeds$1396/moVisit
NuuVim$1892/moVisit

Zepbound Head-to-Head Comparisons

Short-form verdict pages comparing Zepbound to other GLP-1 options with trial-anchored data, FDA-label dosing, and current manufacturer pricing.

Zepbound vs Wegovy
Zepbound delivered 20.9% TBWL in SURMOUNT-1 vs Wegovy's 14.9% in STEP-1 — and SURMOUNT-5 head-to-head confirmed Zepbound −20.2% vs Wegovy −13.7% over 72 weeks.
Last verified 2026-05-27
Zepbound vs Mounjaro
Mounjaro and Zepbound are the same molecule (tirzepatide) from Eli Lilly — Mounjaro is FDA-labeled for type 2 diabetes; Zepbound for obesity and obstructive sleep apnea.
Last verified 2026-05-27
Zepbound vs Ozempic
Ozempic is labeled for type 2 diabetes; Zepbound for obesity and OSA. SURMOUNT-5 head-to-head: tirzepatide -20.2% vs semaglutide -13.7% at 72 weeks.
Last verified 2026-05-27
Zepbound vs Foundayo
Zepbound (tirzepatide) injection delivers ~22.5% TBWL vs Foundayo (orforglipron) oral pill ~11% — but Foundayo skips needles and has no food restriction.
Last verified 2026-05-27
Zepbound vs Saxenda
Saxenda (daily liraglutide 3 mg) delivered ~8% weight loss in SCALE; Zepbound (weekly tirzepatide) hit 20.9% in SURMOUNT-1. Saxenda keeps the pediatric and pregnancy-planning niches.
Last verified 2026-05-28
Zepbound vs Rybelsus
Rybelsus is daily oral semaglutide for T2D only (~3-5% weight loss, strict 30-min fast). Zepbound is weekly injectable tirzepatide for obesity and OSA (~20.9% weight loss).
Last verified 2026-05-28

See all drug-vs-drug verdicts.

Pivotal Zepbound Trial Walkthroughs

Endpoint-by-endpoint breakdowns of the trials that shaped the Zepbound label, with primary-source numbers and FAQs.

SURMOUNT-1
SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) to once-weekly tirzepatide 5 mg, 10 mg, 15 mg, or placebo for 72 weeks. The 15-mg arm lost a mean 20.9% of body weight on the treatment-regimen estimand (NEJM publication) vs 3.1% with placebo; 91% achieved at least 5% loss and 57% achieved at least 20% loss. Every prespecified cardiometabolic measure — waist, systolic blood pressure, fasting insulin, triglycerides, HbA1c — improved. GI adverse events were dose-dependent and discontinuations for AEs ran 4.3-7.1% on tirzepatide vs 2.6% on placebo.
3 · N=2,539 · Last verified 2026-05-27
SURMOUNT-OSA
SURMOUNT-OSA is the pair of phase-3 trials that drove the December 2024 FDA approval of Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity — the first drug ever approved for the condition. Eli Lilly ran two parallel master-protocol cohorts and reported them as one paper (Malhotra 2024 NEJM, PMID 38912654): SURMOUNT-OSA-1 (n=234) randomized adults not using positive airway pressure (PAP) therapy, and SURMOUNT-OSA-2 (n=235) randomized adults already established on PAP. After 52 weeks of weekly tirzepatide at maximum tolerated dose (10 or 15 mg), the apnea-hypopnea index dropped by 25.3 events/hour in cohort 1 (placebo-subtracted −20.0) and 29.3 events/hour in cohort 2 (placebo-subtracted −23.8). Body weight fell about 18-20%, hsCRP dropped roughly 35-40%, and systolic blood pressure fell 7-9 mmHg.
Phase 3 · N=469 · Last verified 2026-05-28
SURMOUNT-2
SURMOUNT-2 randomized 938 adults with obesity and type 2 diabetes to once-weekly tirzepatide 10 mg, 15 mg, or placebo for 72 weeks. The 15-mg arm lost a mean 14.7% of body weight on the treatment-regimen estimand versus 3.2% with placebo, and dropped HbA1c by 2.22 percentage points from a mean baseline of 8.02%. Nearly 87% of 15-mg participants reached at least 5% weight loss and 52% reached 15%, while 91% hit an HbA1c below 7%. The trial answered the question SURMOUNT-1 left open — does tirzepatide work for weight loss when diabetes is on board? — and underpinned Zepbound's positioning for the obesity-plus-T2D population.
3 · N=938 · Last verified 2026-05-28
SURMOUNT-3
SURMOUNT-3 asked the question every patient and payer wants answered: does tirzepatide still work after someone has already lost weight on lifestyle alone? Eli Lilly enrolled 806 adults with obesity into a 12-week intensive lifestyle intervention, kept the 579 who lost at least 5% of their weight, and randomized them 1:1 to tirzepatide (titrated to max-tolerated 10 mg or 15 mg) or placebo for 72 more weeks of treatment, both groups continuing the lifestyle program. From the randomization point, tirzepatide drove an additional 18.4% mean weight loss versus a 2.5% regain on placebo — a placebo-subtracted 20.8 percentage points. Total weight loss across the lead-in and randomized phases reached roughly 26% on tirzepatide. The trial directly parallels STEP-3 (semaglutide plus intensive behavioral therapy) and is the strongest evidence against the argument that GLP-1 medications only work for people who have not yet tried lifestyle changes.
3 · N=579 · Last verified 2026-05-28

Zepbound Patient Questions, Answered

Real patient questions about Zepbound pulled from named subreddits and answered with peer-reviewed trial data.

Top 10 Tirzepatide Questions from Reddit, Answered with Trial Data
10 questions · 11 PubMed citations
Last verified 2026-05-27
Top 10 GLP-1 Insurance Coverage Questions from Reddit, Answered
10 questions · 12 PubMed citations
Last verified 2026-05-28
Top 10 GLP-1 Injection Technique Questions from Reddit, Answered with FDA Labels
10 questions · 11 PubMed citations
Last verified 2026-05-28
Top 10 GLP-1 Plateau Questions from Reddit, Answered
10 questions · 10 PubMed citations
Last verified 2026-05-28

Zepbound Reference Cards

Scannable cheat sheets for dose schedules, missed-dose rules, and red-flag side effects — every number verified against the DailyMed FDA label.

Zepbound Titration Schedule Cheat Sheet (FDA Dose Ladder, Missed-Dose Rules)
Scannable reference card for the Zepbound (tirzepatide) dose ladder pulled directly from the DailyMed Zepbound prescribing information. Six dose steps, 4 weeks per step, three maintenance tiers (5, 10, or 15 mg), a 96-hour missed-dose window, and the red-flag side effects that warrant pausing escalation. For decisions about whether to advance, the FDA label lets prescribers hold a patient at any tolerated maintenance dose — the 15 mg ceiling is the maximum, not a required target.
4 min read · Last verified 2026-05-27
GLP-1 Injection Site Rotation: 8-Week Cheat Sheet (2026)
Wegovy, Ozempic, Zepbound, and Mounjaro all share the same three FDA-approved injection sites: abdomen, front of thigh, and back of upper arm. Reusing the same spot week after week causes lipohypertrophy — thickened fatty tissue that absorbs the drug erratically, leaving appetite suppression and weight-loss results inconsistent. This cheat sheet maps the approved sites, gives an 8-week rotation example, and lists the technique mistakes that send users back to the prescriber.
4 min read · Last verified 2026-05-28
GLP-1 to GLP-1 Switching (2026 Cheat Sheet)
Wegovy → Zepbound, Ozempic → Mounjaro, Saxenda → Wegovy — FDA labels do not address head-to-head switching directly. Starting-dose matrix, wait times between drugs, and red flags during the transition on one scannable page.
5 min read · Last verified 2026-05-28

Ranked PubMed Studies on Zepbound

Curated lists of the highest-impact peer-reviewed studies on Zepbound and related GLP-1 drugs. Every PMID live-verified via PubMed esummary.

Top 10 PubMed Studies on Tirzepatide for Weight Loss (2026)
Ten peer-reviewed tirzepatide weight-loss studies anchored to the SURMOUNT program (SURMOUNT-1 through SURMOUNT-5, plus SURMOUNT-CN and SURMOUNT-OSA), the SYNERGY-NASH liver-fibrosis trial, the SUMMIT HFpEF trial, and the SURPASS-2 head-to-head against semaglutide. Each entry includes the PMID, trial design, primary endpoint, and editorial summary.
10 ranked papers · Last verified 2026-05-27
Top PubMed Studies on GLP-1 Drugs for Obstructive Sleep Apnea (2026)
Nine peer-reviewed studies that built the case for GLP-1 receptor agonists in obstructive sleep apnea (OSA). SURMOUNT-OSA (Malhotra 2024 NEJM) and its 2026 cardiometabolic-risk secondary analysis (Nature Medicine) drove the December 2024 FDA approval of Zepbound for OSA — the first medication of any class with an OSA indication. The list also covers the SCALE Sleep Apnea liraglutide trial, the Sleep AHEAD intensive-lifestyle trial and its 10-year follow-up, a CPAP-vs-liraglutide proof-of-concept RCT, the Wang/Schwab tongue-fat mechanism paper, STEP-HFpEF as adjacent context for OSA-overlap populations, and two 2025-2026 systematic reviews. Each entry includes PMID, NCT, primary endpoint, and editorial summary.
9 ranked papers · Last verified 2026-05-28
Top PubMed Studies on GLP-1 Drugs and Muscle / Lean Mass Loss (2026)
Ten peer-reviewed studies that frame the muscle-loss question on GLP-1 therapy. Most randomized data comes from DEXA substudies of obesity trials — SURMOUNT-1 (Look 2025 Diabetes Obes Metab), the retatrutide phase-2 T2D body-composition substudy (Coskun 2025 Lancet D&E), and the Hendershot 2025 JAMA Psychiatry semaglutide AUD trial — which together show roughly 25-40% of weight lost on a GLP-1 is lean mass, comparable to or slightly worse than diet/exercise weight loss. The list also covers the Lundgren 2021 NEJM liraglutide-plus-exercise RCT, the Locatelli 2024 Diabetes Care resistance-exercise review, the Karakasis 2025 network meta-analysis, the Neeland 2024 mitigation-strategies review, the Tinsley 2024 fundamental body-composition framework, the Linge 2024 Circulation muscle-mass adaptive-vs-maladaptive paper, and the Nunn 2024 activin-receptor antibody preclinical paper as adjacent muscle-preservation context. Each entry includes PMID, journal, primary endpoint where applicable, and editorial summary.
10 ranked papers · Last verified 2026-05-28
Top PubMed Studies on GLP-1 Drugs and Bone Health / Fracture Risk (2026)
Ten peer-reviewed studies that frame the emerging GLP-1 bone-health question. The evidence base is younger and thinner than for cardiovascular or kidney outcomes — most randomized data is from DEXA substudies of obesity weight-loss trials, not dedicated fracture endpoints. Rapid weight loss is known to reduce bone mineral density by roughly 1-3% at the hip and lumbar spine over 12-18 months regardless of how it is achieved, and DEXA substudies of liraglutide and semaglutide have generally found GLP-1-mediated weight loss produces comparable BMD reductions to diet-induced loss. Whether the GLP-1 receptor itself confers an independent bone-protective effect — as proposed by Iepsen's foundational 2015 JCEM trial — remains contested. RCT-level meta-analyses (Mabilleau 2014, Cheng 2019, Zhang 2025) have shown no overall fracture-risk signal in type 2 diabetes populations. Observational and pharmacovigilance work (Ko 2023 JAMA Netw Open, Xiao 2025 FAERS) point toward neutral or favorable fracture profiles versus comparators. Each entry includes PMID, journal, study type, and editorial summary.
10 ranked papers · Last verified 2026-05-28

Related Research on Zepbound

Deep-dive articles from our research desk with primary-source trial data, FDA label verification, and editorial analysis.

Endoscopic Sleeve Gastroplasty (ESG): The Evidence vs GLP-1s and Surgery
Endoscopic sleeve gastroplasty (ESG) is an incisionless stomach-tightening procedure that produced 13.6% weight loss in the MERIT randomized trial - on par with semaglutide, below tirzepatide and surgery. The honest evidence on efficacy, safety, cost, reversibility, and how it compares to a GLP-1.
12 min read12 citations
Gastric Balloon vs GLP-1: Which Wins on Weight Loss, Durability, and Safety?
No head-to-head trial exists, but the shape is clear: a temporary 6-month gastric balloon delivers ~7-15% weight loss that partly reverses after removal, versus a GLP-1's ongoing ~15-21% sustained while taken. The balloon also carries FDA death reports a GLP-1 does not. For most people a GLP-1 or ESG is stronger; the balloon's niche is a short-term jump-start.
10 min read7 citations
ESG vs GLP-1 (Semaglutide and Tirzepatide): The Head-to-Head Evidence
A one-time incisionless procedure or a weekly injection for life? ESG produced ~13.6-16% weight loss vs ~14.9% for semaglutide and ~20.9% for tirzepatide, but no head-to-head trial exists. Efficacy, durability, cost over time, risk, and the combination that beats either alone.
12 min read6 citations
Zepbound (Tirzepatide) and Sex Drive in Women: The Evidence
Zepbound is the largest-weight-loss GLP-1/GIP brand, so its weight-loss-mediated boost to female sexual function may be the biggest of any drug — yet no trial has ever measured female libido as an endpoint. What the evidence supports, plus PCOS and the contraception warning.
10 min read14 citations
Zepbound and Erectile Dysfunction: The Biggest Weight-Loss Lever for ED?
Zepbound (tirzepatide) produces the largest weight loss of any approved agent (SURMOUNT-1 -20.9%), so it offers the biggest weight-mediated erectile opportunity. But there is no direct ED-endpoint trial and no head-to-head vs semaglutide - plausible, not proven.
10 min read11 citations
Mounjaro and Erectile Dysfunction in Type 2 Diabetes: The Dual-Driver Case
Diabetic ED is extremely common. Mounjaro (tirzepatide) improves both glycemia and weight - the two biggest reversible drivers of ED in diabetic men. No tirzepatide trial measured erections, and established neuropathy caps recovery, but the mechanism is well-aimed.
10 min read11 citations

Frequently Asked Questions

Sources & methodology — as of July 2026
  1. 1.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  2. 2.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  3. 3.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
  4. 4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  5. 5.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  6. 6.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.